* To be consumed as directed by physician.
Prutis 150 Mg Capsules
Nintedanib soft Gelatin capsules 150 Mg
Nintedanib is a intracellular tyrosine kinase inhibitor (TKI) with antifibrotic properties, which was one of the first drugs approved for use in idiopathic pulmonary fibrosis (IPF) and has more recently been approved for use in other chronic fibrosing ILDs a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). Nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) in adults with IPF, other progressive fibrosing ILDs and SSc-ILD. Nintedanib also reduces the risk of events indicating ILD progression. Real-world experience in patients with IPF supports the effectiveness of nintedanib in slowing ILD progression. Nintedanib has a manageable tolerability profile in patients with fibrotic ILDs in clinical trials and real-world studies. Also, a long-term safety study is available for more than 4 years.
- To slow the rate of decline in pulmonary function in adult patients with SSc-ILD.
- For the treatment of adults with IPF. 3) For the treatment of adults with chronic fibrosing ILDs with progressive phenotype.
Product Enquiry
